Sa1926 Durability of Anti TNF α Therapy in Ulcerative Colitis: Switching is an Effective Strategy in a Small Subset of Patients

Lilani P. Perera; Yelena Zadvornova; Kia Saeian; Corinne Guilday; Dan Joseph Stein; Amar S. Naik

doi:10.1016/s0016-5085(12)61360-2

Related publications

Article2022

Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses

Shunsuke Fujita, Hajime Honjo, Ryutaro Takada, Akane Hara, Yasuhiro Masuta, Yasuo Otsuka, Kohei Handa, Kosuke Minaga, Shigeyoshi Tsuji, Masatoshi Kudo, Tomohiro Watanabe

Article2021

Delayed-Release Phosphatidylcholine Is Effective for Treatment of Ulcerative Colitis: A Meta-Analysis

Wolfgang Stremmel, Hüseyin Vural, Osman Evliyaoğlu, Ralf Weiskirchen

Article2005

Guideline for anti-TNF-α therapy in psoriatic arthritis

Stuart Kyle, David Chandler, Christopher Em Griffiths, Philip Helliwell, James Lewis, Iain B. McInnes, S. Oliver, Deborah Symmons, Neil McHugh

Article2012

Sa1910 Long Term Outcomes of Crohn's Disease Patients on Maintenance Anti-TNF-α Therapy

Lilani P. Perera, Yelena Zadvornova, David G. Binion, Corinne Guilday, Dan Joseph Stein, Amar S. Naik, Nanda Venu, Kari Best, Susan Skaros

Article2019

P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study

Andrés Yarur, Gerassimos J. Mantzaris, Mark S. Silverberg, Margaret Walshe, Petros Zezos, Dan Joseph Stein, M Bassel, T Lissoos, Claudia Lopez, Athanasios Natsios, Gabriela Radulescu, Haridarshan Patel, Dirk Demuth, Brian Bressler